
Vivian C. Chin
Supervisory Patent Examiner (ID: 17044, Phone: (571)272-7848 , Office: P/2654 )
| Most Active Art Unit | 2747 |
| Art Unit(s) | 2654, 2644, 2695, 2605, 2747, 2608, 2743, 2615, 2614, 2609, 2682 |
| Total Applications | 608 |
| Issued Applications | 319 |
| Pending Applications | 136 |
| Abandoned Applications | 157 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17734764
[patent_doc_number] => 20220220223
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-14
[patent_title] => TREATMENT OF ALLERGIC DISEASES WITH CHIMERIC PROTEIN
[patent_app_type] => utility
[patent_app_number] => 17/711517
[patent_app_country] => US
[patent_app_date] => 2022-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19747
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 111
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17711517
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/711517 | Treatment of allergic diseases with chimeric protein | Mar 31, 2022 | Issued |
Array
(
[id] => 19202855
[patent_doc_number] => 20240174754
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-30
[patent_title] => ANTI-KLRG1 ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 18/552515
[patent_app_country] => US
[patent_app_date] => 2022-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15905
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18552515
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/552515 | ANTI-KLRG1 ANTIBODIES | Mar 24, 2022 | Pending |
Array
(
[id] => 19521138
[patent_doc_number] => 12122847
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-10-22
[patent_title] => Factor VII (FVII(a))/TREM-like transcript 1 (TLT-1) bispecific antibodies
[patent_app_type] => utility
[patent_app_number] => 17/699460
[patent_app_country] => US
[patent_app_date] => 2022-03-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31264
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 263
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17699460
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/699460 | Factor VII (FVII(a))/TREM-like transcript 1 (TLT-1) bispecific antibodies | Mar 20, 2022 | Issued |
Array
(
[id] => 17851916
[patent_doc_number] => 20220281958
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-08
[patent_title] => HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
[patent_app_type] => utility
[patent_app_number] => 17/655503
[patent_app_country] => US
[patent_app_date] => 2022-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 60524
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17655503
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/655503 | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | Mar 17, 2022 | Issued |
Array
(
[id] => 20129443
[patent_doc_number] => 12371747
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-29
[patent_title] => Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
[patent_app_type] => utility
[patent_app_number] => 17/681435
[patent_app_country] => US
[patent_app_date] => 2022-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 50
[patent_figures_cnt] => 114
[patent_no_of_words] => 53313
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 139
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17681435
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/681435 | Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy | Feb 24, 2022 | Issued |
Array
(
[id] => 17792066
[patent_doc_number] => 20220251157
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-11
[patent_title] => IgM-MEDIATED RECEPTOR CLUSTERING AND CELL MODULATION
[patent_app_type] => utility
[patent_app_number] => 17/674438
[patent_app_country] => US
[patent_app_date] => 2022-02-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16196
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17674438
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/674438 | IgM-MEDIATED RECEPTOR CLUSTERING AND CELL MODULATION | Feb 16, 2022 | Abandoned |
Array
(
[id] => 17828476
[patent_doc_number] => 20220265780
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => FACTOR VIII-FC CHIMERIC AND HYBRID POLYPEPTIDES, AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/587941
[patent_app_country] => US
[patent_app_date] => 2022-01-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24769
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17587941
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/587941 | FACTOR VIII-FC CHIMERIC AND HYBRID POLYPEPTIDES, AND METHODS OF USE THEREOF | Jan 27, 2022 | Pending |
Array
(
[id] => 17749667
[patent_doc_number] => 20220227871
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-21
[patent_title] => ANTI-PD-L1 ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 17/579517
[patent_app_country] => US
[patent_app_date] => 2022-01-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19446
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 57
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17579517
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/579517 | ANTI-PD-L1 ANTIBODY | Jan 18, 2022 | Abandoned |
Array
(
[id] => 17704639
[patent_doc_number] => 20220204645
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-30
[patent_title] => ANTIBODIES THAT RECOGNIZE RED BLOOD CELL ANTIGENS
[patent_app_type] => utility
[patent_app_number] => 17/571075
[patent_app_country] => US
[patent_app_date] => 2022-01-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13776
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17571075
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/571075 | Antibodies that recognize red blood cell antigens | Jan 6, 2022 | Issued |
Array
(
[id] => 19034202
[patent_doc_number] => 20240084017
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-14
[patent_title] => MONOCLONAL ANTIBODY AGAINST HUMAN MAC-1 AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/259958
[patent_app_country] => US
[patent_app_date] => 2021-12-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6722
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18259958
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/259958 | MONOCLONAL ANTIBODY AGAINST HUMAN MAC-1 AND USES THEREOF | Dec 29, 2021 | Pending |
Array
(
[id] => 17761534
[patent_doc_number] => 20220235146
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-28
[patent_title] => ANTI-IgE ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/541932
[patent_app_country] => US
[patent_app_date] => 2021-12-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41212
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17541932
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/541932 | Anti-IgE antibodies | Dec 2, 2021 | Issued |
Array
(
[id] => 17460339
[patent_doc_number] => 20220073644
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-10
[patent_title] => BISPECIFIC ANTIBODY EXHIBITING INCREASED ALTERNATIVE FVIII-COFACTOR-FUNCTION ACTIVITY
[patent_app_type] => utility
[patent_app_number] => 17/528371
[patent_app_country] => US
[patent_app_date] => 2021-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24918
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -1
[patent_words_short_claim] => 116
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17528371
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/528371 | Bispecific antibody exhibiting increased alternative FVIII-cofactor-function activity | Nov 16, 2021 | Issued |
Array
(
[id] => 18212457
[patent_doc_number] => 20230058721
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-23
[patent_title] => Procoagulant Antibodies
[patent_app_type] => utility
[patent_app_number] => 17/522949
[patent_app_country] => US
[patent_app_date] => 2021-11-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 56494
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17522949
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/522949 | Procoagulant Antibodies | Nov 9, 2021 | Abandoned |
Array
(
[id] => 18901447
[patent_doc_number] => 20240016932
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-18
[patent_title] => CHIMERIC ANTIGEN RECEPTOR
[patent_app_type] => utility
[patent_app_number] => 18/034999
[patent_app_country] => US
[patent_app_date] => 2021-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9426
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18034999
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/034999 | CHIMERIC ANTIGEN RECEPTOR | Nov 8, 2021 | Pending |
Array
(
[id] => 17837752
[patent_doc_number] => 20220275057
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-01
[patent_title] => FACTOR VIII CHIMERIC PROTEINS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/519719
[patent_app_country] => US
[patent_app_date] => 2021-11-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57344
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17519719
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/519719 | FACTOR VIII CHIMERIC PROTEINS AND USES THEREOF | Nov 4, 2021 | Pending |
Array
(
[id] => 18893818
[patent_doc_number] => 20240009303
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-11
[patent_title] => COMBINATION VACCINE FOR PROTECTING SWINE AGAINST VARIOUS DISORDERS
[patent_app_type] => utility
[patent_app_number] => 18/250106
[patent_app_country] => US
[patent_app_date] => 2021-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6388
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18250106
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/250106 | COMBINATION VACCINE FOR PROTECTING SWINE AGAINST VARIOUS DISORDERS | Oct 27, 2021 | Pending |
Array
(
[id] => 18895495
[patent_doc_number] => 20240010980
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-11
[patent_title] => NATURAL KILLER CELLS WITH ENHANCED ACTIVITY
[patent_app_type] => utility
[patent_app_number] => 18/249991
[patent_app_country] => US
[patent_app_date] => 2021-10-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17454
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -54
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18249991
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/249991 | NATURAL KILLER CELLS WITH ENHANCED ACTIVITY | Oct 26, 2021 | Pending |
Array
(
[id] => 17587727
[patent_doc_number] => 11325983
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-05-10
[patent_title] => Bispecific antibodies
[patent_app_type] => utility
[patent_app_number] => 17/501548
[patent_app_country] => US
[patent_app_date] => 2021-10-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31201
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 148
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17501548
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/501548 | Bispecific antibodies | Oct 13, 2021 | Issued |
Array
(
[id] => 17356842
[patent_doc_number] => 20220017638
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-20
[patent_title] => METHOD OF TREATING ATHEROSCLEROSIS
[patent_app_type] => utility
[patent_app_number] => 17/498112
[patent_app_country] => US
[patent_app_date] => 2021-10-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24361
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17498112
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/498112 | METHOD OF TREATING ATHEROSCLEROSIS | Oct 10, 2021 | Abandoned |
Array
(
[id] => 17482274
[patent_doc_number] => 20220089778
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-24
[patent_title] => COAGULATION FACTOR BINDING PROTEINS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/450423
[patent_app_country] => US
[patent_app_date] => 2021-10-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33214
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17450423
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/450423 | COAGULATION FACTOR BINDING PROTEINS AND USES THEREOF | Oct 7, 2021 | Abandoned |